Timbetasin Acetate

Summary

Timbetasin Acetate (CHEMBL4594314) is a phase-3 clinical-stage protein; indicated across 4 conditions including dry eye syndrome and epidermolysis bullosa dystrophica.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594314
Name	Timbetasin Acetate
Type	Protein
Max phase	3

Also known as: GBT-201, Rgn-137, RGN-137, RGN-259, Thymosin b4, Timbetasin acetate, TIMBETASIN ACETATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906
epidermolysis bullosa dystrophica	2	MONDO:0006543	Orphanet:303
junctional epidermolysis bullosa	2	MONDO:0017612	MONDO:0017612
keratitis	1	MONDO:0003085	EFO:0009449

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05555589	PHASE3	RECRUITING	Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT02597803	PHASE2/PHASE3	COMPLETED	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
NCT02600429	PHASE3	TERMINATED	Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
NCT02974907	PHASE3	COMPLETED	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
NCT03937882	PHASE3	COMPLETED	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
NCT03578029	PHASE2	TERMINATED	Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).